There is no FDA-approved treatment for AL amyloidosis; however, chemotherapy targeting plasma cells, such as cyclophosphamide, bortezomib (Velcade), and dexamethasone (CyBorD), and/or autologous stem cell transplant, are standard of care and can elicit deep and durable hematologic responses.7-9 Fig...
The author discusses the treatment for amyloidosis, which is a group of diseases that are caused by extracellular accumulation of protein. She says that such diseases are can be acquired or hereditary, and that transthyretin amyloid causes hereditary and acquired amyloidosis with a range of symptoms...
This review summarizes current cognitive enhancing approaches and addresses trends in the development of new symptomatic agents for the treatment of cognitive and behavioral abnormalities of AD. New directions in the treatment of cognitive enhancing agents are presented, and advances in the development of...
Thus, given the importance of Ca2+ and Zn2+ homeostasis for brain functioning, strategies aimed at restoring the brain balance of these ions are emerging as promising avenues for the treatment of AD with several therapeutic approaches based on the so-called ‘metals hypothesis’ already showing en...
Managing Systemic Light-Chain Amyloidosis Drugs effective in multiple myeloma are usually active in AL, depending on side effects. New agents such as bortezomib and lenalidomide have shown promising... Comenzo,L Raymond - 《J Natl Compr Canc Netw》 被引量: 127发表: 2007年 ...
An international trial with a new standard of care for patients with AL amyloidosis,Australasian Leukaemia and Lymphoma Group (ALLG),Interventional,Phase 3
Previously approved medications that have gained new FDA approval for the treatment of additional medical conditions.
2. The changes in drug development strategies for AD Currently, two classes of drugs—cholinesterase inhibitors (i.e., donepezil, rivastigmine, and galantamine) and antagonists of the N-methyl-D-aspartate (NMDA) receptor (i.e., memantine)—are approved for the treatment of AD [24], [25]....
The clarification of mechanisms of cardiac damage is offering new potential therapeutic targets, and several treatment options with a relevant impact on prognosis are now available. 展开 关键词: Cardiac amyloidosis Heart failure NT-proBNP Cardiac imaging Diastolic function Systolic function Cardiac toxicity...
In this study on 25 patients, the researchers at Karolinska Institutet found that a dose of 400 mg daily ofvenetoclax, a medication currently used to treat different types of leukemia, was effective in the treatment of heavily pre-treated MM and AL-amyloidosis patients, a disease associated with...